Cite
HARVARD Citation
Dummer, R. et al. (n.d.). 3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma. European journal of cancer. pp. S667-S668. [Online].